Sangamo Therapeutics Stock (NASDAQ: SGMO)

Sangamo Therapeutics

SANGAMO THERAPEUTICS INC

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

wall street chart shutter2

Earnings

Equities

Government

Market Summary

News

Futures

Commodities

Economics

Federal Reserve

Pre-Market Outlook

Markets

Analyst Ratings

ETFs

AAPL

AMZN

BGLC

CXAI

MULN

NMTC

NVDA

SGMO

U.S. stock futures continued to decline on Friday after a bloodbath on Thursday following the introduction of Donald Trump&#39;s tariffs.

Stocks Set To Continue Crashing After Worst Selloff Since 2020: Tariff Announcement Was &#39;100% Smoot Hawley Disguised As Thoughtful Policy,&#39; Says Expert

Movers_Stocks

Movers

Trading Ideas

ADPT

ENTO

HRTG

IIIN

LION

LSAK

MLNK

OLMA

RNAC

SHCO

SLSR

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics Inc

Penny Stocks

Press Releases

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Kodiak Sciences

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Lyell Immunopharma

Seres Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Neurogene

Nkarta

Puma Biotechnology

RAPT Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tango Therapeutics

RBC Capital

HC Wainwright & Co.

Truist Securities

Jefferies

Wells Fargo

Comments

Sangamo Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga